These results suggested that CART-secreted aIL6 and IL1RA could effectively prevent significant elevation of IL6 and IL1B during CRS, therefore minimizing IL6- and IL1-associated cytokine toxicity and neurotoxicity. The gene discussed is IL6; the disease is congenital rubella syndrome.